Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery
Related Experiment Video
Updated: Apr 6, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Rong Huang1, Yu Sun2, Xiang-yang Zhang3
1School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210096, China.
Abstract:
Platinum-based drugs have been widely used for the treatment of malignant tumors. However, their applications are limited by severe side effects for their lack of selectivity for cancer cells. The development of antibody drug conjugates (ADCs) have provided a platform to reduce drug toxicity and improve drug efficacy. Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery. This conjugate is believed to be cleaved by cathepsin B, leading to a 1,6-elimination reaction and activation of drug release. Herceptin-Pt(II) is evaluated to have approximately loaded with 6.4 moles platinum drugs per mole of antibody. We demonstrate that Herceptin-Pt(II) retain high and selective binding affinity for HER2 protein and HER2-positive SK-BR-3 cancer cells. The in vitro cytotoxicity tests indicate that Herceptin-Pt(II) exhibits much higher cytotoxicity than oxaliplatin against SK-BR-3 cells. More importantly, Herceptin-Pt(II) shows no obvious inhibition against the growth of both MCF-7 and MDA-MB-231 cells, which express lower levels of HER2. Furthermore, compared with free oxaliplatin, Herceptin significantly improved the cellular uptake of platinum drugs in SK-BR-3 cells. In summary, Herceptin-platinum (II) conjugate is a remarkable and potent platform for efficient and cancer cell specific delivery.
Insights
A novel Herceptin-platinum (II) conjugate enhances targeted delivery of platinum drugs to HER2-positive cancer cells, improving efficacy and reducing side effects. This antibody-drug conjugate (ADC) shows potent, selective cytotoxicity against HER2-positive tumors.
Area of Science:
- Oncology
- Pharmacology
- Bioconjugation Chemistry
Background:
- Platinum-based chemotherapy is a cornerstone in cancer treatment but suffers from severe systemic toxicity due to poor cancer cell selectivity.
- Antibody-drug conjugates (ADCs) offer a promising strategy to enhance therapeutic efficacy and minimize off-target side effects by delivering cytotoxic agents directly to cancer cells.
Purpose of the Study:
- To develop and evaluate a novel antibody-drug conjugate (ADC) linking Herceptin (an anti-HER2 antibody) with a platinum (II) drug.
- To assess the targeted delivery, efficacy, and safety profile of the Herceptin-platinum (II) conjugate in HER2-positive cancer models.
Main Methods:
- Conjugation of a platinum (II) drug to Herceptin via a cathepsin B-cleavable peptide linker, forming Herceptin-Pt(II).
- Characterization of the conjugate's platinum loading (6.4 moles Pt/mole antibody) and binding affinity to HER2 protein and HER2-positive SK-BR-3 cells.
- In vitro evaluation of cytotoxicity against HER2-positive (SK-BR-3) and HER2-low (MCF-7, MDA-MB-231) cancer cell lines, and assessment of cellular uptake compared to free oxaliplatin.
Main Results:
- Herceptin-Pt(II) demonstrated high and selective binding to HER2-positive cells.
- The conjugate exhibited significantly enhanced in vitro cytotoxicity against SK-BR-3 cells compared to oxaliplatin.
- Minimal cytotoxicity was observed against HER2-low expressing cell lines (MCF-7, MDA-MB-231), indicating target specificity.
- Herceptin-mediated delivery substantially increased platinum drug uptake in SK-BR-3 cells.
Conclusions:
- The Herceptin-platinum (II) conjugate represents a potent and effective platform for targeted cancer therapy.
- This ADC strategy successfully enhances drug accumulation and achieves cancer cell-specific delivery, offering a promising approach to improve platinum-based chemotherapy.
- The developed conjugate holds potential for treating HER2-positive malignancies with improved therapeutic index.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle